Apogee TherapeuticsAPGE reported a "best case scenario" Monday for its potential rival to Regeneron Pharmaceuticals'REGN blockbuster eczema drug, Dupixent. Apogee Therapeutics stock rallied in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results